CREDIT AGREEMENT Dated as of October 13, 2016 amongCredit Agreement • February 23rd, 2017 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • New York
This CREDIT AGREEMENT is entered into as of October 13, 2016, among VERTEX PHARMACEUTICALS INCORPORATED, a Massachusetts corporation (the “Borrower”), the Subsidiaries of the Borrower as are or may from time to time become parties to this Agreement as Subsidiary Guarantors (defined herein), the Lenders (defined herein), and BANK OF AMERICA, N.A., as Administrative Agent, Swingline Lender and an L/C Issuer.
EMPLOYMENT AGREEMENTEmployment Agreement • February 23rd, 2017 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”) is made and entered into as of this 14th day of November, 2015, by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the “Company”), and Michael Parini (the “Executive”).
February 26, 2013Vertex Pharmaceuticals Inc / Ma • February 23rd, 2017 • Pharmaceutical preparations • Massachusetts
THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 23rd, 2017 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This Third Amended and Restated Employment Agreement (this “Agreement”) amends and restates, effective as of this 26th day of February, 2013, that certain Second Amended and Restated Employment Agreement made and entered into as of the 15th day of November, 2012, (the “Original Agreement”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the “Company”), and Amit Sachdev (the “Executive”).
Amendment No. 7 Research, Development and Commercialization Agreement, Dated May 24, 2004 by and between Vertex Pharmaceuticals Incorporated And Cystic Fibrosis Foundation Therapeutics IncorporatedVertex Pharmaceuticals Inc / Ma • February 23rd, 2017 • Pharmaceutical preparations
Whereas, Cystic Fibrosis Foundation Therapeutics Incorporated, a Delaware corporation (“CFFT”), and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Vertex”), are parties to that certain Research, Development and Commercialization Agreement dated May 24, 2004, as previously amended by Amendment No. 1 thereto dated January 6, 2006, Amendment No. 2 thereto dated as of January 1, 2006, Amendment No. 3 thereto dated November 20, 2006, Amendment No. 4 thereto dated August 20, 2007, Amendment No. 5 thereto dated as of April 1, 2011, and Amendment No. 6 thereto dated March 29, 2012 (collectively, the “Agreement”). Capitalized terms used herein without specific definition shall have the meanings set forth in the Agreement.
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • February 23rd, 2017 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of February 9, 2017 (this “Amendment”), modifies that certain Credit Agreement, dated as of October 13, 2016 (as amended, restated, amended and restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”), among VERTEX PHARMACEUTICALS INCORPORATED, a Massachusetts corporation (the “Borrower”), certain Subsidiaries of the Borrower party thereto from time to time as Subsidiary Guarantors, the Lenders party thereto from time to time, and Bank of America, N.A., as Administrative Agent, Swingline Lender and an L/C Issuer. Capitalized terms used herein and not defined shall have the meaning assigned to such terms in the Credit Agreement.
